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Background and purpose: Previously, we showed a good correlation between pathology and an automat-
ically generated PET-contour in rectal cancer. This study analyzed the effect of the use of PET–CT scan on
the interobserver variation in GTV definition in rectal cancer and the influence of PET–CT on treatment
volumes.
Materials and methods: Forty two patients diagnosed with rectal cancer underwent an FDG–PET–CT for
radiotherapy planning. An automatic contour was created on PET-scan using the source-to-background
ratio. The GTV was delineated by 5 observers in 3 rounds: using CT and MRI, using CT, MRI and PET
and using CT, MRI and PET auto-contour. GTV volumes were compared and concordance indices (CI) were
calculated. Since the GTV is only a small portion of the treatment volume in rectal cancer, a separate anal-
ysis was performed to evaluate the influence of PET on the definition of the CTV used in daily clinical
practice and the caudal extension of the treatment volumes.
Results: GTV volumes based on PET were significantly smaller. CIs increased significantly using PET and
the best interobserver agreement was observed using PET auto-contours. Furthermore, we found that in
up to 29% of patients the CTV based on PET extended outside the CTV used in clinical practice. The caudal
border of the treatment volume can be tailored using PET-scan in low seated tumors. Influence of PET on
the position of the caudal border was most pronounced in high seated tumors.
Conclusion: PET–CT increases the interobserver agreement in the GTV definition in rectal cancer, helps to
avoid geographical misses and allows tailoring the caudal border of the treatment volume.
 2012 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 102 (2012) 371–376Pre-operative radiotherapy has become an essential part of the
treatment of most patients with rectal cancer, since it is very effec-
tive in reducing the risk of a locoregional recurrence [1]. Combin-
ing radiotherapy and chemotherapy results in downsizing and in
up to 10–33% of patients pathological complete responses (pCR)
have been reported [2–5]. Patients with a good clinical response
may benefit from less invasive surgery, like sphincter-saving sur-
gery or transanal endoscopic microsurgery (TEM). Even, in selected
cases, a wait-and-see policy might be safe [6]. These innovative
modified surgical approaches may lead to a better quality of life.
Thus, it would be attractive to further increase the probability of
a good tumor response, e.g. by increasing the dose to the tumor
[5,7,8]. To achieve higher doses to the tumor, a simultaneous inte-
grated boost technique has been shown to be feasible [9–11]. In or-
der to identify the boost volume easily and reliably, high quality
imaging is important. MRI is considered the most accurate stagingd Ltd. All rights reserved.
, Dr. Tanslaan 12, 6229 ET
en).method for rectal cancer [12–14], but its role in a precise determi-
nation of the boost volume is unknown [15]. For PET-imaging it has
been reported that it is reliable in defining tumor size in rectal can-
cer [16] and has the additional advantage that it can easily be ac-
quired in treatment position simultaneously with a CT-scan,
which is needed for treatment planning.
Another reason why it is important to define more precisely the
primary tumor in rectal cancer is that it may help to reduce long
term toxicity that is observed after radiotherapy for rectal cancer
[17,18], through a further reduction of treatment fields. As our
group has shown before, 3-D conformal planning results in a better
PTV coverage and dose homogeneity as compared to standard 3- or
4-field techniques based on bony anatomy [19]. However, the use
of more conformal techniques, like IMRT, poses the risk of geo-
graphical misses. Furthermore individual delineation makes it pos-
sible to better spare normal tissues. A better identification of the
primary tumor allows avoiding irradiation of the sphincter in se-
lected cases and reducing the volume of small bowel in high seated
tumors, resulting in less toxicity. It has been shown that positive
lymph nodes are most frequently located at the level of the tumor.
372 PET–CT for rectal cancer delineationThe proximal spread of lymph nodes is limited to 5 cm from the
distal margin of the tumor and the distance to the most distal
nodes is 4 cm at maximum [20,21].
Furthermore, an analysis of the Dutch TME trial showed that in
primary resectable rectal cancer short course radiotherapy is espe-
cially effective in the prevention of anastomotic recurrences
[22,23]. This finding confirms that it is important to know the exact
location of the tumor in order to safely reduce radiotherapy treat-
ment fields.
For these reasons we hypothesized that the use PET–CT can help
to define the GTV in rectal cancer more accurate leading to a better
tailored definition of the treatment volume, that it would diminish
interobserver variability and diminish the time needed to define
the GTV. Furthermore we hypothesized that the influence of the
use of PET–CT on treatment volume would be larger in low seated
tumors as compared to high rectal tumors, because of the low soft
tissue contrast on CT in the lower part of the pelvis.Methods and materials
For this study 42 patients diagnosed with rectal cancer (cT2-
4N0-2M0) were selected. Patients were scheduled to undergo a
neo-adjuvant treatment consisting of chemoradiotherapy (28 
1.8 Gy with concurrent capecitabine 825 mg/m2 bid). All patients
underwent an FDG–PET–CT scan for radiotherapy planning on an
integrated PET–CT scanner (Truepoint Biograph 40, Siemens Erlan-
gen, Germany). The PET-scan protocol has been described in detail
earlier [24]. PET–CT images were fused and an automatic contour
around the primary tumor was created, using the Signal-to-Back-
ground-Ratio (SBR)-method as described earlier [25,26] using ded-
icated software (Esoft 5.0, Siemens MI, Erlangen, Germany). This
contouring method has been shown to have a good correlation
with pathology in rectal cancer [16].
We balanced the number of patients with low- and high-seated
tumors (22 high, 20 low). For this study high seated tumors had a
caudal border P7 cm from the anal verge.
For delineation, fixed window/level settings were used (400/50
for CT and 30000/15000 for PET). In PET-scans not showing enough
contrast using these settings, an adjusted W/L setting was used,
identical for all 5 observers.GTV delineation and interobserver variability
The GTV was delineated by 5 observers: 2 radiation-oncologists
sub-specialized in gastro-intestinal (GI) tumors, 1 senior-resident,
1 radiation-technologist and 1 radiologist. At the time of delinea-
tion clinical details were available and presented in a standardized
format to each observer including the findings on digital rectal
examination and the endoscopy and pelvic MR-imaging reports.
Each study set was delineated 3 times by each observer in 3
consecutive rounds. During each delineation round observers
had, in addition to the standardized clinical information, access
to different imaging information, creating 3 sets of GTV contours
per observer. In each round an MR-scan was available. MR and
CT were not fused and MR was projected on a second screen.
Round 1: MR- and CT-images only (CT–GTV (GTVCT)), round 2:
MR-, CT- and PET-images (PET–GTV (GTVPET)) and in round 3 in
addition to the MR-, CT- and PET-images the automatic generated
contour on PET was provided (automatic GTV (GTVauto)). In the
third round observers were asked to edit the provided contour,
in such a way to obtain a clinically acceptable GTV. For each obser-
ver, the delineation rounds were spaced with a minimum interval
of 4 weeks, to prevent bias from a preceding delineation round.
Observers were blinded to each other’s delineations.Time needed for each delineation was registered by the observ-
ers. The volumes of the different GTVs were collected from the
planning system and compared. Pairs of contours from the 3 differ-
ent delineation methods were compared by calculating the
concordance index (CI), defined as the ratio of the intersection
and the union of the two volumes [27,28].
CI ¼ ðA \ BÞðA [ BÞ
Differences in GTV delineation were analyzed for the total pa-
tient group as well as for high- and low-seated tumors separately.CTV delineation and interobserver variability
Since the GTV is only a small part of the clinical target volume in
the current treatment of rectal cancer, 3 observers also delineated
the complete CTV as used in daily clinical practice (CTVcompl),
including regional lymph nodes, according to our local protocol
as described earlier [19]. In brief, the CTVcompl included at least
3 cm of the rectal wall in the oral and aboral directions, to cover
possible intramural tumor spread, the mesorectal subsite, poster-
ior pelvic subsite, and the regional lymph nodes at risk, which were
defined by contouring the internal iliac vessels with a margin of
5 mm and the obturator region for low seated tumors (<7 cm from
the anal verge in this protocol). The obturator region was delin-
eated as proposed by Roels et al. [29]. The CTV of the primary tu-
mor was obtained by circumferential expansion of the GTVs with
0.5 cm, resulting in CTVCT, CTVPET and CTVauto. The percentages of
the different CTVs located outside the CTVcompl were analyzed.
We were particularly interested in the caudal tumor extension.
There is evidence that the risk of microscopic disease in lymph
nodes >4 cm caudal from the caudal border of the primary tumor
is very limited [20,21]. Reducing the caudal CTV extension could
result in a reduced radiation dose delivered to the anal sphincter,
decreasing the risk of sphincter dysfunction as described in pa-
tients undergoing pre-operative radiotherapy followed by sphinc-
ter sparing surgery [18,30]. Therefore we also analyzed if the
caudal border intramural margin differed between the CT- and
PET-based delineations.Statistics
SPSS 17.0 (SPSS, Chicago, IL) was used to perform statistical
analysis. For the comparison of the differences in time needed to
perform the delineations a paired-samples t-test was used. The
volumes of the GTVs, CIs of both methods, as well as the percent-
ages of CTV lying outside the CTVcompl and differences in caudal
borders were compared using the Wilcoxon signed rank test, be-
cause data did not follow a normal distribution. Two-sided
p-values are provided; p-values <0.05 were considered significant.
Results
The availability of PET images resulted in about 40% decrease in
the time needed to complete GTV delineation (mean time GTVCT
4.1 min, GTVPET 2.5 min (p < 0.001) and GTVauto 1.6 min (p < 0.001)).
The volumes for each observer are shown in Table 1. GTV vol-
umes were significantly smaller using PET-scan (mean GTVCT
46.8 cm3 vs. mean GTVPET 28.8 cm3 (p < 0.001)). Editing automati-
cally created contours resulted in the smallest volumes (mean
GTVauto 18.2 cm3 (p < 0.001)).
An example of the delineation of 2 patients is depicted in Fig. 1.
Conformity indices increased when PET information was added,
reflecting a better agreement between observers. The mean confor-
mity index (mean ± SD) for the 5 observers was 0.79 ± 0.17 (range:
Table 1
Mean GTV volumes for the 5 different observers using three different delineation methods.
CT-based PET-based PET-auto
Mean Range Mean Range p Mean Range pa pb
All observers 46.8 6.3 185.7 28.8 1.5 131.9 <0.001 23.6 2.4 96.3 <0.001 <0.001
Observer 1 41.2 6.3 159.3 26.0 1.5 107.3 <0.001 23.3 2.4 88.1 <0.001 0.27
Observer 2 52.7 11.6 168.5 26.2 3.8 115.3 <0.001 23.0 2.8 87.5 <0.001 0.24
Observer 3 48.8 9.6 185.7 37.2 7.7 131.9 <0.001 25.3 2.5 93.6 <0.001 <0.001
Observer 4 43.6 7.3 166.6 29.6 2.6 119.7 <0.001 23.6 2.7 89.7 <0.001 <0.001
Observer 5 47.4 7.9 167.5 25.2 4.5 128.7 <0.001 22.9 2.5 89.9 <0.001 0.21
a Compared with CT-based delineation.
b Compared with PET-based delineation.
Fig. 1. Example of the delineations by 5 observers in a patient with a high-seated (1) and a low-seated tumor (2), based on CT-only (a), PET–CT (b) and PET–CT with auto-
contour (c).
Fig. 2. Concordance index according to delineation method (CT, PET–CT and PET–
CT with autocontour) and divided in low seated (67 cm from the anal verge) and
high seated tumors. +: p = 0.31, : p = 0.50, : p = 0.94, §: p = 0.103, –: p < 0.001, ⁄:
p < 0.001.
J. Buijsen et al. / Radiotherapy and Oncology 102 (2012) 371–376 3730–0.98) using CT only in combination with MRI, 0.82 ± 0.16 (range:
0.10–1.00, p = 0.103) using PET-data without automatically createdcontours and 0.93% ± 10.5 (range: 0.28–1.00, p < 0.001) using PET
auto-contours (Fig. 2). Using CT-scans only, in 2 cases a complete
disagreement between observers occurred (reflected by a CI of 0).
No differences were found between low- and high-seated tu-
mors: 0.78 vs 0.79 (p = 0.31) for CT-only, 0.82 vs. 0.82 (p = 0.50)
for PET-manual and 0.93 vs 0.92 (p = 0.94) for PET with auto-con-
tours (Fig. 2).
The analysis of the CTVs showed that, with the addition of PET,
in some patients a part of the tumor CTV was not covered by the
CTVcompl. The mean CI for CTVPET was 0.98 (range: 0.27–1.00) and
for CTVauto 0.98 (0.29–1.00). For CTVPET the percentage of volume
lying outside CTVcompl exceeded 5% in 8 cases (19%) (4 times in ob-
server 1, 2 times in observer 2 and 2 times in observer 3). For
CTVauto this was the case in 12 delineations (29%) (6 times in obser-
ver 1, 3 times in observer 2 and 2 times in observer 3). In 1 patient
more than 75% of the CTVPET and CTVauto was lying outside the
CTVcompl in 2 observers. This was a high seated tumor which was
not correctly delineated based on CT and MR only, but was cor-
rectly identified on PET.
On average, the caudal border of the intramural margin was lo-
cated 0.6 cm more cranial if based on automatic PET-contours as
compared to CT. In 7 patients (17%), the caudal border of the
PET-based margin was located 1 cm or more caudal than the CT-
based margin for at least one observer. Four of them had a high
seated tumor, 3 had a low seated tumor. In 3 of these patients
the intramural margin extended P1 cm caudally based on PET
374 PET–CT for rectal cancer delineationfor all 3 observers. In 19 (45%) patients the caudal border of the
PET-margin was located P1 cm higher than the CT-margin. In 6
patients this difference of P1 cm was observed in all 3 observers,
in another 6 patients in 2 observers and in the remaining 7 patients
in 1 observer. Sixteen of these tumors were located high and 3
were located low. On average the caudal border of PET-margin of
high-seated tumors was located 1.1 cm more cranial than CT-mar-
gin. For low seated tumors the difference was negligible (Fig. 3).
The difference between low- and high-seated tumors was statisti-
cally significant.
Discussion
To the best of our knowledge, this is the first study looking at the
influence of the use of automatically created PET-contours on GTV
delineation and interobserver variability in rectal cancer. As has
been shown earlier, the SBR method results in contours with a very
good correlation with pathology [16]. The smallest GTV volumes
are created using PET-based autocontours as compared to CT-based
contours and manual PET-based contours (23.6 cc vs. 28.8 cc vs.
46.9 cc). This study confirms that the use of PET-based autocon-
tours leads to a very good interobserver agreement, reflected by a
mean CI of 0.93 for automatic PET-contours as compared to 0.82
(manual PET-contours) and 0.79 (CT-based contours). Furthermore,
we found that PET-scan may help to avoid geographical misses in
selected cases, especially in very low and very high located tumors
and therefore may be helpful to define an adequate boost volume.
In addition it could help to reduce treatment fields leading to a
reduction of the amount of sphincter in the radiation volume, pos-
sibly leading to less late sphincter related toxicity and it allows for
GTV-boosting in dose escalation trials.
A better interobserver agreement using PET-scan has been
shown for the delineation of lung-, brain- and head and neck tu-
mors [31–33]. Furthermore it has been demonstrated that the
use of automatically created contours results in better agreement
than visual interpretation of PET [34]. Obviously, visual interpreta-
tion depends on many factors, like window/level settings and the
display mode of the PET information (for example grayscale or col-
ormode) and experience of the observers. In this study 5 observers
with different experience and background were asked to delineate
the GTVs. Although it is difficult to draw firm conclusions, weFig. 3. Mean difference ± SD in cm of the 3 observers who delineated the complete
treatment volume between the most caudal extension of the intramural margin
based on CT and the caudal boundary based on the automatic PET-based contour. A
negative value means that the caudal border based on PET was located more cranial
than the CT-based border (i.e. in that case the volume based on PET was shorter in
caudal direction).observed that the differences in volumes differed statistically sig-
nificant for all but 2 observer combinations when using CT data
only. Differences in volume became smaller using PET-data and
CIs decreased for all observers, indicating that PET is helpful for
observers with different levels of experience in delineation of
rectal tumors.
Other groups have looked at the influence of PET on target vol-
ume delineation before. Ciernik et al. [35] was the first group that
published about the use of PET–CT in delineation for rectal cancer
using a growing region algorithm. They found a good correlation
with GTVs created manually on CT, but did not analyze the influ-
ence of PET information on delineation decisions by the physician.
No comparison was made between different observers. In a study of
Bassi et al. [36] tumor delineation was done by 2 radiation-oncolo-
gists together. They concluded that GTVs based on PET were signif-
icantly smaller than CT-based GTVs, which is in line with our
findings. Patel et al. compared the delineations of tumor and lymph
nodes in 6 rectal cancer patients who underwent an FDG–PET as
well as FLT–PET [37]. In contrast to our findings, they did not ob-
serve clear differences in GTV volumes, but the interobserver agree-
ment was better using PET. No differences between FDG–PET and
FLT–PET were seen and no SUV-based auto-contour was used.
Results of rectal cancer treatment have improved markedly in
the last decades, due to better surgical techniques and the wide-
spread use of radiotherapy [1]. However, the use of radiotherapy
results in long-term toxicity in a substantial part of patients. There-
fore, it is important to make a better patient selection on one hand
and to tailor treatment fields as much as possible on the other
hand. Irradiation of the sphincter may result in problems with fecal
continence [38,39]. In the Dutch TME trial 62% of patients without
a stoma reported fecal incontinence or soiling in the radiotherapy
and surgery arm versus 38% in the surgery only arm [18]. This
study shows that the use of PET-scan can help to better tailor treat-
ment fields. Especially the caudal border of the radiation fields can
be limited in an important proportion of patients, resulting in a
lower sphincter dose and a lower dose to the distal rectal wall in
higher seated tumors, without the risk of geographical misses. The-
oretically this could lead to less late toxicity. We hypothesized that
the influence of PET on GTV volume and caudal extension of the
treatment volume would be largest in lower seated tumors. This
study showed that influence of PET was not different between
low- and high-seated tumors. Therefore, the use of PET may be
beneficial to all rectal cancer patients. When looking specifically
at the influence of imaging modality on the position of the caudal
border of the treatment volume (Fig. 3), it can be concluded that
PET is helpful to individualize this border. In some patients this
border will be located more cranial when based on PET, possibly
resulting in a lower dose to the sphincter and distal rectal wall,
while in others it will be located more distal. For the analysis of
the caudal border we included a 3 cm margin in the course of
the rectal wall in both directions. In our protocol we do not stop
this margin at the border of the sphincter. For example: if the cau-
dal border of the tumor is located 2 cm cranial to the sphincter,
1 cm of the anal canal was included in the intramural margin. It
can be argued whether this is really necessary or whether one
could see the anorectal junction as an anatomical barrier. Of course
this can influence the results of our analysis. Recent literature sug-
gests that distal surgical margins as close as 1 cm may be safe, but
this is based on the surgical data of patients who have been treated
with pre-operative radiotherapy in majority [40,41]. Therefore, we
do not feel comfortable at the moment to leave the complete
sphincter out of the treatment volume in very low lying tumors
and use the intramural margin based on PET-scan.
As stated in the introduction, adequate identification of the tu-
mor is essential to create a reliable boost volume. This allows to
study if boosting of the primary tumor results in more pathological
J. Buijsen et al. / Radiotherapy and Oncology 102 (2012) 371–376 375complete responses and if this can lead to the use of less invasive
surgery. This study shows that use of PET results in a good agree-
ment between observers and our pathology validation study
showed a very strong agreement between tumor length defined by
automatic PET-contours and measured by the pathologist in the sur-
gical specimen. If we assume that the representation of the position
of the tumor and tumor edges is accurate, we can conclude that PET–
CT makes it possible to define a reliable GTV in rectal cancer.
Although we think that this assumption is very plausible, no analysis
of the position of the tumor on PET–CT and in vivo has been per-
formed. Therefore, in clinical practice this method should be used
with caution and a clinical prospective evaluation is necessary.
A second problem that has to be solved to define an adequate
boost volume is the internal organ motion, which can be quite sub-
stantial in the case of rectal cancer. It has been shown that espe-
cially in the cranial part of the mesorectum deformations can be
quite substantial and that these deformations are caused mainly
by differences in bowel filling [42].
Although a PET-scan adequately images the primary tumor and
can be used for tumor delineation, it is not reliable for the distinction
between benign and pathological lymph nodes [43]. The specificity
is acceptable, but the sensitivity is rather low [44–46]. Therefore,
additional imaging is strongly needed to adequately identify posi-
tive nodes. MR in combination with special contrast agents seems
to be a promising method [47]. For this study we did not compare
different PET segmentation algorithms, because we found a good
correlation between pathology and SBR-based PET-contours. How-
ever, the SBR-method has several disadvantages [48]. It is dependent
on many parameters, so that each modification in the process makes
it necessary to perform a new calibration and each scanner has to be
calibrated separately. In addition this method does not perform well
if the source-to-background ratio is low. In future projects we will
compare the performance of other segmentation methods with
the SBR method in rectal cancer. Apart from a useful tool in delinea-
tion, FDG–PET can also be helpful to get insight in tumor heteroge-
neity. Our group has shown that in NSCLC residual metabolic
active areas after radiotherapy are the areas with the highest uptake
before treatment [49,50]. Recently we showed that this is also the
case for rectal cancer [51]. Another step for the future could there-
fore be the development of sub-boosting techniques.
In conclusion, PET–CT reduces interobserver variation and vol-
umes in GTV definition in rectal cancer, enables tailoring treatment
fields, especially in cranio-caudal direction, and makes it possible
to define volumes for boosting.References
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